8月4日 - ** 药物开发商INmune Bio INMB.O早盘股价上涨7%至2.74美元
** 该公司称其治疗一种前列腺癌的疗法达到了一项早中期研究的主要和次要目标
** INMB表示，INKmune疗法 "在试验的三个剂量水平上都具有很好的耐受性，显示出极佳的安全性"，而这正是试验的主要目标。
** 因此，联合公司停止了该研究的进一步注册工作
** 包括本交易日的走势在内，该股今年累计下跌 41.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.